Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update

J. Tajti, Délia Szok, Anett Csáti, L. Vécsei

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Migraine as a highly disabling pain condition influences the daily activities of those affected, including children and adolescents. The pathomechanism of migraine is not fully understood, and the different types of prophylactic antimigraine drugs that are applied are not specific for migraine. There is a need for preventive treatment in the event of frequent migraine attacks, an impairment of the quality of life, severe accompanying or aura symptoms, and the failure of acute drug treatment. The following pharmacological classes are recommended: antidepressants, antiepileptics, antihistamines, beta-adrenergic receptor blockers, and calcium ion channel antagonists, besides onabotulinum toxin A and nutraceuticals (butterbur). The most urgent goal as concerns pharmaceutical innovation is the development of pathomechanism-based antimigraine drugs and personalized therapy tailored to the children and adolescents.

Original languageEnglish
Article number1
Pages (from-to)1-9
Number of pages9
JournalCurrent Pain and Headache Reports
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

    Fingerprint

Keywords

  • Antidepressants
  • Antiepileptics
  • Antihistamines
  • Beta-adrenergic receptor blockers
  • Butterbur
  • Calcium ion channel antagonists
  • Efficacy
  • Migraine
  • Onabotulinum toxin A
  • Pediatric
  • Prophylactic
  • Safety
  • Therapy
  • Tolerability

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this